Time for evidence based research policy

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Edgerton, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE; PENICILLIN DERIVATIVE; SULFONAMIDE;

BIOTECHNOLOGY; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; EDITORIAL; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; MANAGEMENT; UNITED KINGDOM;

BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; POLICY MAKING; UNITED KINGDOM;

EID: 84975291691     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3146     Document Type: Editorial

References (8)

1. Owen G, Hopkins MM. Science, the state and the city: Britain's struggle to succeed in biotechnology. Oxford University Press, 2016doi:10.1093/acprof:oso/9780198728009. 001.0001.
2. Nuffield Council on Bioethics. Emerging biotechnologies: technology, choice and the public good. nuffieldbioethics.org/wp-content/uploads/2014/07/Emerging-biotechnologies- full-report-web-0.pdf.
3. Nightingale P, Martin P. The myth of the biotech revolution, Trends in Biotechnology. 2004: 22; 11. 564-569.10.1016/j.tibtech.2004.09.010.
4. Rose H, Rose S. Genes, cells and brains: the Promethean promises of the new biology. Verso, 2014.
5. Sheridan DJ. Medical science in the 21st century: sunset or new dawn? Imperial College Press. 2012.
6. Le Fanu J. The rise and fall of modern medicine. 2nd ed. Abacus, 2011.
7. Carlson R. Estimating the biotech sector's contribution to the US economy. Nat Biotechnol 2016;34:247-55. doi:10.1038/nbt.3491. pmid:26963545.
8. Edgerton D. The shock of the old: technology and global history since 1900. Profile, 2007.